Bio-Rad Laboratories, Inc. Class B Stock News
$379.99
1.36%
NYSE, Nov 04, 04:15 pm EST.
Closed.
Index
Industry
Bio-Rad Laboratories, Inc. Class B Stock News
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced financial results for the third quarter ended September 30, 2026. Norman Schwartz, Bio-Rad's Chief Executive Officer, stated: “Our third-quarter results reflect the steady progress we have been driving. We returned to cu...
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that its Chief Financial Officer, Roop K. Lakkaraju, will participate in a fireside chat event during Bernstein Insights Healthcare Leaders and Disruptors 3rd Annual Forum on Thursday, September 24, 2026, at 8:50 AM East...
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that its Chief Financial Officer, Roop K. Lakkaraju, will participate in a fireside chat event during Wells Fargo's 21st Annual Healthcare Conference on Wednesday, September 9, 2026, at 3:45 PM Eastern Time (12:45 PM Pac...
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced financial results for the second quarter ended June 30, 2026. Norman Schwartz, Bio-Rad's Chairman and Chief Executive Officer, stated: “Second-quarter reported revenue was flat year-over-year, with growth in Clinical Dia...
U.S. biotechnology industry trade group BIO worked with the Food and Drug Administration on plans announced on Monday to speed clinical trials and expects the next initiative will aim to standardize the agency's review of drug applications, CEO John Crowley said on Tuesday.
Activist investor Elliott Investment Management has built a sizeable stake in U.S. diagnostics supplier Bio-Rad Laboratories , and plans to push the company to boost its underperforming stock price, the Wall Street Journal reported on Sunday.
Elliott also has a stake in German lab-equipment supplier Sartorius, where Bio-Rad is also an investor.
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
